OS Therapies’ (OSTX) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital restated their buy rating on shares of OS Therapies (NYSE:OSTX) in a report published on Monday,Benzinga reports. D. Boral Capital currently has a $20.00 price target on the stock.

A number of other research analysts have also recently commented on the company. Maxim Group upped their price target on OS Therapies from $8.00 to $15.00 and gave the company a “buy” rating in a research report on Thursday, January 16th. Lake Street Capital assumed coverage on shares of OS Therapies in a report on Wednesday, April 2nd. They set a “buy” rating and a $19.00 price objective on the stock. Three research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Buy” and an average target price of $18.00.

OS Therapies Trading Up 2.3 %

OS Therapies stock opened at $1.34 on Monday. The business’s 50 day simple moving average is $1.68 and its 200 day simple moving average is $2.61. OS Therapies has a 12 month low of $1.24 and a 12 month high of $7.00.

Insider Buying and Selling at OS Therapies

In other OS Therapies news, major shareholder Shalom Auerbach sold 16,720 shares of the stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $6.74, for a total value of $112,692.80. Following the sale, the insider now directly owns 2,531,211 shares in the company, valued at $17,060,362.14. This represents a 0.66 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 13.80% of the company’s stock.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in OS Therapies stock. CM Management LLC boosted its holdings in shares of OS Therapies Inc (NYSE:OSTX) by 120.1% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 110,044 shares of the company’s stock after buying an additional 60,044 shares during the period. CM Management LLC owned approximately 0.51% of OS Therapies worth $471,000 as of its most recent SEC filing.

OS Therapies Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.